In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cambrex Bio Science Walkersville Inc.

Division of Lonza Group Ltd.

Latest From Cambrex Bio Science Walkersville Inc.

ZelleRx Corp.

Imagine a type of cell that combines the advantages of a natural defense mechanism with the desirable attributes of a biopharmaceutical. The founders of ZelleRx Corp. believe they've found the best of both worlds in a particular type of natural killer cell, known as NK-92. Using the cell line, ZelleRx intends to develop cell therapies for cancer, initially renal cell carcinoma and melanoma.

Rewriting Fate: The Stem Cell Transplant Business

Physicians, patients, and companies can now see the stem cell transplant business taking shape. Stem cell trials are finally in progress, allowing investors and corporate partners to finally see just how effective this multi-billion-dollar opportunity to replace many highly problematic organ transplants, and dramatically expand the procedures into new areas, can be. Beyond the lack of clinical conformation, stem cell transplantation therapy has been held back by the inability to culture large quantities of cells--as with whole organ transplants, there simply isn't enough tissue to go around. For the most part, companies have had to propose autologous transplantation strategies or, at best, transplants from one donor for just a few patients--an economically difficult-to-justify business. Geron, the only player in this group to have benefited from the last nine months of biotech stock mania, holds a key competitive advantage: its ability to use embryonic stem cells (ESCs) to create, theoretically, nearly infinite quantities of any cell in the body. But recent developments have stirred the competitive pot: a number of companies have created methods for growing enough adult stem cells to provide them to significant numbers of patients. Meanwhile, researchers have transformed fully committed adult stem cells into cells of different lineages, raising the possibility that alternatives to ESCs for tissue replacement or repair exist. The transplant replacement business--regenerative medicine--has caught the public's attention. Nonetheless, the stem cell industry has remained a start-up's trade, and it's easy to see why: large-company experiences in the area have not, for the most part, been happy ones, as companies face the issues of installing unpharma-like infrastructures to deliver personalized therapy, as well as ethical concerns, which must be given appropriate consideration. But these and other hurdles shouldn't obscure the growing opportunity. Stem cell therapy, so long a therapeutic chimera, now seems ripe for commercial exploitation.
BioPharmaceutical Platform Technologies

Link Technology Inc.

Diagnostics. Link Technology is developing an assay for the early detection of gram-negative septicemia. The assay measures levels of endotoxin in the blood of patients at risk of developing endotoxemia. The start-up is also developing an A1 adenosine agonist-based compound that may prevent the endotoxin-related cascade from occurring in the lung.
Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • BioWhittaker Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Lonza Group Ltd.
  • Senior Management
  • Thomas N Bird, VP, Biotechnology
  • Contact Info
  • Cambrex Bio Science Walkersville Inc.
    Phone: (301) 898-7025
    8830 Biggs Ford Rd.
    Walkersville, MD 21793-0127